About this document
Cost-Efficiency of Biosimilar Trastuzumab by t4qnjfx4yq is a document available to read on EtoBox.
This study investigates the cost-efficiency and expanded access of converting to the biosimilar trastuzumab-dkst from reference trastuzumab in metastatic breast cancer. The analysis shows significant cost savings from conversion, which could allow for increased patient access to treatment without additional budget impact. Overall, trastuzumab-dkst is found to be cost-efficient compared to both intravenous and subcutaneous forms of trastuzumab across various patient weights.
- Author
- t4qnjfx4yq
- Language
- EN